Taysha Gene Therapies, Inc. (TSHA)
4.385
0.00 (0.00%)
USD |
NASDAQ |
Oct 07, 13:42
Taysha Gene Therapies Enterprise Value : 1.030B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 1.030B |
| October 05, 2026 | 1.062B |
| October 02, 2026 | 1.108B |
| October 01, 2026 | 1.143B |
| September 30, 2026 | 1.186B |
| September 29, 2026 | 1.225B |
| September 28, 2026 | 1.225B |
| September 25, 2026 | 1.121B |
| September 24, 2026 | 1.160B |
| September 23, 2026 | 1.199B |
| September 22, 2026 | 1.280B |
| September 21, 2026 | 1.241B |
| September 18, 2026 | 1.234B |
| September 17, 2026 | 1.280B |
| September 16, 2026 | 1.251B |
| September 15, 2026 | 1.248B |
| September 14, 2026 | 1.231B |
| September 11, 2026 | 1.234B |
| September 10, 2026 | 1.280B |
| September 09, 2026 | 1.339B |
| September 08, 2026 | 1.384B |
| September 04, 2026 | 1.423B |
| September 03, 2026 | 1.413B |
| September 02, 2026 | 1.436B |
| September 01, 2026 | 1.456B |
| Date | Value |
|---|---|
| August 31, 2026 | 1.452B |
| August 28, 2026 | 1.478B |
| August 27, 2026 | 1.540B |
| August 26, 2026 | 1.560B |
| August 25, 2026 | 1.618B |
| August 24, 2026 | 1.544B |
| August 21, 2026 | 1.583B |
| August 20, 2026 | 1.589B |
| August 19, 2026 | 1.693B |
| August 18, 2026 | 1.615B |
| August 17, 2026 | 1.622B |
| August 14, 2026 | 1.537B |
| August 13, 2026 | 1.550B |
| August 12, 2026 | 1.685B |
| August 11, 2026 | 1.774B |
| August 10, 2026 | 1.674B |
| August 07, 2026 | 1.735B |
| August 06, 2026 | 1.664B |
| August 05, 2026 | 1.703B |
| August 04, 2026 | 1.618B |
| August 03, 2026 | 1.482B |
| July 31, 2026 | 1.508B |
| July 30, 2026 | 1.513B |
| July 29, 2026 | 1.426B |
| July 28, 2026 | 1.378B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 228.94M |
| Protalix Biotherapeutics, Inc. | 187.79M |
| Humacyte, Inc. | 118.92M |
| Agenus, Inc. | 583.85M |
| Amgen, Inc. | 260.96B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.64M |
| Total Expenses (Quarterly) | 46.64M |
| EPS Diluted (Quarterly) | -0.1264 |
| Earnings Yield | -9.86% |
| Normalized Earnings Yield | -9.517 |